How have ALGS shares performed in 2024?

Aligos Therapeutics' stock was trading at $0.6640 at the beginning of the year. Since then, ALGS stock has increased by 25.8% and is now trading at $0.8350. View the best growth stocks for 2024 here .

Are investors shorting Aligos Therapeutics?

Aligos Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 868,800 shares, an increase of 137.6% from the March 15th total of 365,600 shares. Based on an average trading volume of 376,700 shares, the short-interest ratio is presently 2.3 days. View Aligos Therapeutics' Short Interest .

When is Aligos Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our ALGS earnings forecast .

How were Aligos Therapeutics' earnings last quarter?

Aligos Therapeutics, Inc. (NASDAQ:ALGS) released its earnings results on Tuesday, March, 12th. The company reported ($0.22) EPS for the quarter, topping analysts' consensus estimates of ($0.27) by $0.05. The company had revenue of $2.68 million for the quarter, compared to analysts' expectations of $3.20 million. Aligos Therapeutics had a negative net margin of 607.03% and a negative trailing twelve-month return on equity of 116.41%.

When did Aligos Therapeutics IPO?

Aligos Therapeutics (ALGS) raised $150 million in an IPO on Friday, October 16th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P.Morgan, Jefferies and Piper Sandler served as the underwriters for the IPO and Cantor was co-manager.

How do I buy shares of Aligos Therapeutics?

Shares of ALGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ALGS

Aligos Therapeutics (ALGS) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free ALGS Stock Alerts

$0.84

-0.06 (-6.70%)

(As of 04/16/2024 ET)

Compare

Today's Range: $0.80
▼
$0.91
50-Day Range: $0.64
▼
$1.13
52-Week Range: $0.54
▼
$1.38

Volume: 247,318 shs
Average Volume: 363,240 shs
Market Capitalization: $63.18 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Aligos Therapeutics alerts:

Aligos Therapeutics MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
1.15% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.80
Upright™ Environmental Score
News Sentiment: 0.86
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.83) to ($0.82) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.41 out of 5 stars

Medical Sector

509th out of 930 stocks

Biological Products, Except Diagnostic Industry

83rd out of 153 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Aligos Therapeutics.

3.0

Short Interest

Percentage of Shares Shorted
1.15% of the outstanding shares of Aligos Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Aligos Therapeutics has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Aligos Therapeutics has recently increased by 137.64%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Aligos Therapeutics does not currently pay a dividend.
Dividend Growth
Aligos Therapeutics does not have a long track record of dividend growth.

4.8

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Aligos Therapeutics has received a 76.60% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services of the circulatory system", "Clinical research services for metabolic diseases", and "Basic medical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Aligos Therapeutics is -0.80.

2.7

News and Social Media Coverage

News Sentiment
Aligos Therapeutics has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Aligos Therapeutics this week, compared to 1 article on an average week.
Search Interest
Only 2 people have searched for ALGS on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Aligos Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
16.50% of the stock of Aligos Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
60.43% of the stock of Aligos Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Aligos Therapeutics are expected to grow in the coming year, from ($0.83) to ($0.82) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Aligos Therapeutics is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Aligos Therapeutics is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Aligos Therapeutics has a P/B Ratio of 0.68. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Aligos Therapeutics Stock (NASDAQ:ALGS)

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

ALGS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ALGS Stock News Headlines

April 11, 2024 | americanbankingnews.com

Short Interest in Aligos Therapeutics, Inc. (NASDAQ:ALGS) Rises By 137.6%

April 9, 2024 | finance.yahoo.com

Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024

April 16, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 9, 2024 | americanbankingnews.com

Aligos Therapeutics (NASDAQ:ALGS) Stock Price Up 2.9%

April 3, 2024 | finance.yahoo.com

Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects

March 27, 2024 | globenewswire.com

Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies

March 16, 2024 | uk.investing.com

Aligos Therapeutics Inc (ALGS)

March 15, 2024 | markets.businessinsider.com

Maintaining a Hold: Balancing Promise and Risk in Aligos Therapeutics’ Clinical Pipeline

April 16, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 14, 2024 | finance.yahoo.com

Aligos Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

March 12, 2024 | markets.businessinsider.com

Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results

March 12, 2024 | benzinga.com

Recap: Aligos Therapeutics Q4 Earnings

March 12, 2024 | globenewswire.com

Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results

March 8, 2024 | markets.businessinsider.com

Piper Sandler Reaffirms Their Buy Rating on Aligos Therapeutics (ALGS)

March 6, 2024 | seekingalpha.com

Tracking Baker Brothers Portfolio - Q4 2023 Update

March 5, 2024 | globenewswire.com

Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024

February 26, 2024 | globenewswire.com

Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024

February 24, 2024 | msn.com

Aligos Therapeutics (ALGS) Price Target Increased by 300.00% to 4.08

February 23, 2024 | benzinga.com

Aligos Therapeutics Stock (NASDAQ:ALGS) Earnings Dates and Earning Calls

February 23, 2024 | benzinga.com

Aligos Therapeutics Stock (NASDAQ:ALGS), Short Interest Report

February 20, 2024 | finance.yahoo.com

Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024

February 20, 2024 | globenewswire.com

Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024

February 19, 2024 | finance.yahoo.com

Aligos Therapeutics, Inc. (ALGS)

February 15, 2024 | investing.com

Aligos Therapeutics bolsters executive team with new VPs

February 13, 2024 | finance.yahoo.com

Aligos Therapeutics Strengthens Finance Leadership Team with Two New Appointments

February 10, 2024 | msn.com

Aligos Therapeutics in portfolio reorganization focused on NASH, COVID assets

January 26, 2024 | msn.com

Aligos Therapeutics Launches Voluntary Option Exchange Program

See More Headlines

Receive ALGS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aligos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/12/2024
Today: 4/16/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:ALGS
CUSIP: N/A
CIK: 1799448
Web: www.aligos.com
Phone: 800-466-6059
Fax: N/A
Employees: 66
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($1.59)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-87,680,000.00
Net Margins: -607.03%
Pretax Margin: -559.49%
Return on Equity: -116.41%
Return on Assets: -75.38%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.90
Quick Ratio: 5.90

Sales & Book Value

Annual Sales: $15.53 million
Price / Sales: 4.07
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.23 per share
Price / Book: 0.68

Miscellaneous

Outstanding Shares: 75,670,000
Free Float: 63,184,000
Market Cap: $63.18 million
Optionable: Optionable
Beta: 2.34

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Dr. Lawrence M. Blatt MBA (Age 62)
Ph.D., CEO, President & Chairman of the Board
Comp: $832.73k
Dr. Julian A. Symons DPHIL (Age 62)
Executive VP & Chief Scientific Officer
Comp: $618.66k
Ms. Lesley Ann Calhoun CPA (Age 58)
Executive VP & CFO
Kristina Engeseth
VP and Head of People & Culture
Dr. Matthew W. McClure M.D. (Age 52)
Executive VP & Chief Medical Officer
Dr. Sushmita M. Chanda DABT (Age 57)
Ph.D., Executive Vice President of Translational Safety Sciences
Dr. David B. Smith Ph.D.
Executive VP & Head of Chemical Operations
Dr. Tse-I Lin Ph.D.
VP of Early Compound Development & Belgian Site Head

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ALGS Stock Analysis - Frequently Asked Questions

How have ALGS shares performed in 2024?: Aligos Therapeutics' stock was trading at $0.6640 at the beginning of the year. Since then, ALGS stock has increased by 25.8% and is now trading at $0.8350.
View the best growth stocks for 2024 here.
Are investors shorting Aligos Therapeutics?: Aligos Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 868,800 shares, an increase of 137.6% from the March 15th total of 365,600 shares. Based on an average trading volume of 376,700 shares, the short-interest ratio is presently 2.3 days.
View Aligos Therapeutics' Short Interest.
When is Aligos Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our ALGS earnings forecast.
How were Aligos Therapeutics' earnings last quarter?: Aligos Therapeutics, Inc. (NASDAQ:ALGS) released its earnings results on Tuesday, March, 12th. The company reported ($0.22) EPS for the quarter, topping analysts' consensus estimates of ($0.27) by $0.05. The company had revenue of $2.68 million for the quarter, compared to analysts' expectations of $3.20 million. Aligos Therapeutics had a negative net margin of 607.03% and a negative trailing twelve-month return on equity of 116.41%.

When did Aligos Therapeutics IPO?: Aligos Therapeutics (ALGS) raised $150 million in an IPO on Friday, October 16th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P.Morgan, Jefferies and Piper Sandler served as the underwriters for the IPO and Cantor was co-manager.
How do I buy shares of Aligos Therapeutics?: Shares of ALGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ALGS) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Aligos Therapeutics (ALGS) Stock Price, News & Analysis

Aligos Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Aligos Therapeutics Stock (NASDAQ:ALGS)

ALGS Stock Price History

ALGS Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

ALGS Stock Analysis - Frequently Asked Questions

Overall MarketRank^™